It is also under development for paraganglioma and pheochromocytoma as second line therapy It was also under development for the treatment of primary mediastinal large B cell lymphoma, metastatic ...

It is also under development for paraganglioma and pheochromocytoma as second line therapy It was also under development for the treatment of primary mediastinal large B cell lymphoma, metastatic ...

Results from the trial will be presented at an upcoming medical meeting. “Pheochromocytoma and paraganglioma are rare tumors that form in and around the adrenal glands, and currently ...

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma. The U.S. Food and Drug Administration (FDA) has ...

Objective—To determine if the 8 cm upper limit for mediastinal width applies in the trauma setting of today. To define the upper limit of normal mediastinal width for supine chest films. Methods—A ...

Comparison of laparoscopic radiofrequency ablation with percutaneous radiofrequency ablation in the treatment of chronic hepatitis B-related hepatocellular carcinoma involving specific sites: A ...

thorax.dk Background: A study was undertaken to evaluate the clinical impact of endoscopic ultrasound guided fine needle aspiration biopsy (EUS-FNA) in patients with mediastinal masses suspected of ...

Mediastinal haematoma post permanent pacemaker insertion (PPI) is a rare complication. We report the case of a woman in her 60s with symptomatic complete heart block, who developed symptoms of ...

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025. The FDA granted priority review to a supplemental new ...

Results from the trial will be presented at an upcoming medical meeting. “Pheochromocytoma and paraganglioma are rare tumors that form in and around the adrenal glands, and currently, there are no ...